Benefits
Joint pain and stiffness reduction
One placebo-controlled oral trial gave 64 people with chronic knee osteoarthritis the cetylated fatty acid complex for 68 days; they did better on knee function measures than those on placebo. A second oral trial in 48 people compared it against the prescription drug meloxicam for 30 days, had no placebo group, and found no difference between the two groups. The lead author of the placebo trial has commercial ties to the ingredient.
Improved joint mobility and range of motion
In the single placebo-controlled oral trial, 64 people with knee osteoarthritis had better knee flexion range of motion and functional scores after 68 days than those given placebo. That is one small maker-affiliated trial that has not been independently repeated, done in people who already had osteoarthritis. Nothing in it measured cartilage or joint fluid, so there is no basis for saying the ingredient changes joint structure.
Topical cream study (contained menthol, not an oral product)
The topical study tested a skin cream containing cetylated fatty acids together with menthol in people with arthritis, and reported less pain and better physical function. Menthol is itself a topical pain reliever, so the result cannot be credited to the fatty acids alone. The study had no control group, and because this was a cream applied to the skin, it says nothing about what an oral capsule does.
Cell membrane effects (laboratory study only)
This is a proposed mechanism, not a demonstrated benefit. In a laboratory study on cultured cells, the Celadrin fatty acid mixture lowered inflammatory signals (IL-6, MCP-1 and TNF) and encouraged cartilage-type cell development. Membrane fluidity has never been measured in people taking the supplement, so treat this as a hypothesis about how it might work.
Mechanism of action
Synovial membrane effects (proposed, unmeasured in people)
The proposed idea is that cetylated fatty acids become part of joint cell membranes and change how those cells behave. No human study of this ingredient has measured synovial fluid volume, viscosity or joint lubrication, and none has looked at whether osteoarthritis progresses more slowly. Treat this as a hypothesis rather than something that has been shown to happen.
Inflammatory mediator reduction
The suggested anti-inflammatory route is that these fatty acids change the fat make-up of cell membranes, leaving less arachidonic acid available to the COX and LOX enzymes that produce inflammatory messengers. The only supporting data come from cells in a dish, where the Celadrin mixture lowered IL-6, MCP-1 and TNF. Prostaglandin E2 changes have not been demonstrated in people taking it.
Cartilage cell effects seen in a dish
In a laboratory study on cultured cells, the Celadrin fatty acid mixture pushed cells toward cartilage-type development and lowered inflammatory markers. Whether any of that happens inside a human joint is unknown. No trial has imaged or measured cartilage in people taking this ingredient, so there is no evidence that it protects or rebuilds cartilage.
Clinical trials
Randomized, double-blind, placebo-controlled trial of oral Celadrin® (cetylated fatty acid complex, 1,050 mg/day) vs placebo in 64 patients with knee osteoarthritis for 68 days. Reported outcomes were knee range of motion and functional performance. (Hesslink et al. 2002, J Rheumatol)
64 patients with knee OA. 68-day intervention.
Cetylated fatty acids improved knee range of motion and functional performance compared with placebo over 68 days. Limitations: this is a single small trial in 64 people who already had diagnosed knee osteoarthritis, it has not been independently repeated, and it does not tell you what the ingredient does for a healthy joint. The membrane mechanism offered to explain the result was not measured in the participants.
Study of a skin-applied cream containing cetylated fatty acids together with menthol, in people with arthritis. (Kraemer et al. 2005, J Strength Cond Res). It used a single treatment group with no control arm. Menthol is itself a topical pain reliever, so the cream's effect cannot be separated from it, and a skin cream cannot support claims for an oral supplement.
Adults with arthritis, using a cream on the skin rather than an oral supplement.
The cream reduced pain scores and improved physical function in people with arthritis. The study had no control group, so the improvement cannot be attributed to the cream alone, and the menthol in the formula could account for some or all of the relief. These results apply to a product rubbed on the skin and say nothing about oral capsules.